Compare BLCO & GTLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLCO | GTLB |
|---|---|---|
| Founded | 1853 | 2011 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 4.7B |
| IPO Year | 2022 | 2021 |
| Metric | BLCO | GTLB |
|---|---|---|
| Price | $15.03 | $27.81 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 27 |
| Target Price | $18.45 | ★ $37.17 |
| AVG Volume (30 Days) | 404.4K | ★ 6.8M |
| Earning Date | 04-29-2026 | 06-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,101,000,000.00 | $955,224,000.00 |
| Revenue This Year | $8.65 | $18.72 |
| Revenue Next Year | $5.59 | $16.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 6.47 | ★ 25.81 |
| 52 Week Low | $11.44 | $18.73 |
| 52 Week High | $18.92 | $52.38 |
| Indicator | BLCO | GTLB |
|---|---|---|
| Relative Strength Index (RSI) | 40.00 | 51.30 |
| Support Level | $14.55 | $20.18 |
| Resistance Level | $15.67 | $34.06 |
| Average True Range (ATR) | 0.38 | 1.87 |
| MACD | -0.02 | -0.48 |
| Stochastic Oscillator | 25.91 | 20.00 |
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
GitLab Inc operates on an all-remote model. GitLab is a complete DevSecOps platform delivered as a single application. It operates in two competitive landscapes: DevOps point solutions and DevOps platforms. In terms of point solutions that are stitched together, GitLab's offering is substantially different in that it is one platform, one codebase, one interface, and a unified data model that spans the entire DevSecOps lifecycle. DevOps platforms, the principal competitor is Microsoft Corporation, following their acquisition of GitHub. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. It is located in the United States, Europe, & the Asia Pacific. It focused on accelerating innovation & broadening the distribution of its platform to companies across the world.